Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : anika research(anik) -- Ignore unavailable to you. Want to Upgrade?

To: doc who wrote (125)	6/28/1998 12:34:00 AM
From: Wolfgangus	Read Replies (2) \| Respond to of 328

Copy of my post on Yahoo! There is no question that the recent rise in price is related to anticipation of FDA approval. I expect the decline on Friday was related to the usual pre-weekend profit taking on "story stocks". For example, check out rumored takeover candidate Mellon Bank's multipoint loss on Friday. If it were to have occurred for more than one day mid-week, it would have been more ominous. Probably some initial continued selling pressure at Monday's open is in order, then a brisk recovery. For all believers in ANIK's product, whose reduced side-effect profile over BIOX's is impressive, this may be your last chance to add to your holdings at these levels. When a stock moves as fast as ANIK has recently, significant news is always imminent. If approved, I believe the medical community (of which I am a member) will rapidly switch to the new product as they have repeatedly when improved drugs have been approved in recent years. Information is just too readily available to both patients and doctors for this not to be the case. Best of fortune to all with noisy knees Wolfgangus